Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.TaiGen’s nemonoxacin meets Phase I endpoint
The multinational Phase II clinical trial, with an enrollment of 265 patients in three arms, showed nemonoxacin 750mg once daily in an oral dose over a period of
The multinational Phase II clinical trial, with an enrollment of 265 patients in three arms, showed nemonoxacin 750mg once daily in an oral dose over a period of
EpiCept has recently analyzed the imaging data from the first eight patients enrolled in the study who had measurable Computed Tomography (CT) perfusion scans. These patients received doses
Mr Waldron’s resignation will be effective as of April, 2008 end, although he will remain a company consultant for at least one year. The company will commence a
The randomized, double-blinded, placebo-controlled, sequential ascending single intravenous dose study of TG-0054 will evaluate the safety, tolerability, pharmacokinetics and the biomarkers, the CD34+ stem cells and the CD133+
The study is designed as a two-part, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of KNS-760704 oral tablets. It will be conducted at approximately 20
The preliminary results of the 28-day, 30-patient, randomized, double-blind, placebo-controlled, crossover study showed that P-552-02 was safe and well tolerated, both locally in the oral cavity and systemically.
The estimated purchase price of $11.1 million is based on performance-based earn-out payments over the next two years. At closing, $8.3 million of the purchase price was paid
Previously, the company’s board of directors has approved a 1-for-17 reverse split of its outstanding common stock. The number of shares of the company’s outstanding common stock will
Allion has acquired Biomed for $48 million in cash, 9.35 million shares of Allion common and series A-1 preferred stock and the assumption of $18.6 million of Biomed
This supplemental new drug application (sNDA) was for the additional indication of Frova for the short-term (six days per month) prevention of menstrual migraine. Endo is continuing to